Biogen Runs Into More Headwinds !!!!It has been reported that Biogen's Ad treatment is causing severe case of ARIA , the case reported to the FOIA states that all have required hospital admittance and 1 case reported was life threatening . Not looking good for Biogen . Buy Cassava Sciences this year from $2.78 to a high of $146.00 per share it's amazing they have only 40 million shares and $278.00 million in the bank and there's the exit of the Promis management team to join SAVA , I own shred in both ARFXF and SAVA , but as of right NOW there's no comparison between this performer and Hearsay best in class horrible performer .